Stock listing

NASDAQ:ERAS Erasca, Inc. Stock

Home listing (NASDAQ) of Erasca, Inc.

Follow Erasca, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ERAS

$13.61 USD -0.15 (-1.1%)

Close on Nov 20, 2026

Past year +389.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$13.13 – $14.31 USDNov 20, 2026
Volume
11.07M sharesNov 20, 2026
Market cap
$4.78B USDAt the close on Nov 20, 2026 · price × 351.0M shares outstanding
52-week range
$2.75 – $24.28 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$79.44M USDMedian day 4.42M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Erasca, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ERAS · Home$13.61 USD-0.15 (-1.1%)11,072,619$13.13$14.31$13.13$13.76Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ERAS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$13.61-0.15-1.1%$13.13$14.31$13.1311,072,619
$13.76-0.13-0.9%$13.97$14.14$13.038,941,061
$13.89-1.22-8.1%$15.51$15.69$13.608,789,965
$15.11-0.55-3.5%$15.49$15.84$14.875,827,312
$15.66-0.12-0.8%$15.29$15.83$14.178,533,403
$15.78-1.02-6.1%$16.22$16.22$15.164,897,335
$16.80+1.32+8.5%$15.78$17.34$15.5813,794,006
$15.48-0.13-0.8%$15.43$15.66$15.005,984,545
$15.61+1.20+8.3%$14.57$15.69$14.134,701,552
$14.41+1.14+8.6%$13.42$14.43$13.114,030,116
$13.27-1.64-11.0%$14.91$15.18$13.176,687,563
$14.91+0.27+1.8%$15.09$15.09$14.183,494,665
$14.64+0.59+4.2%$14.30$15.00$14.073,798,381
$14.05-0.30-2.1%$14.76$15.38$13.724,388,524
$14.35-0.63-4.2%$14.66$15.01$14.043,749,182
$14.98-0.14-0.9%$15.11$15.45$14.662,280,740
$15.12-0.10-0.7%$15.20$15.32$14.453,391,417
$15.22+0.23+1.5%$14.95$15.26$14.725,825,490
$14.99+0.60+4.2%$14.58$15.47$14.556,466,115
$14.39+0.35+2.5%$13.99$14.45$13.443,498,640
$14.04-0.45-3.1%$14.22$14.65$13.822,296,073
$14.49-0.13-0.9%$14.82$15.05$14.383,845,038
$14.62+1.00+7.3%$13.40$14.97$13.104,218,224
$13.62+0.23+1.7%$13.73$13.98$13.344,263,888
$13.39-1.48-10.0%$14.87$14.87$13.277,089,200
$14.87+0.17+1.2%$14.71$15.26$14.368,481,000
$14.70-0.08-0.5%$14.41$15.08$14.294,747,500
$14.78-0.68-4.4%$15.25$15.58$14.505,313,600
$15.46-0.57-3.6%$15.89$16.01$15.324,280,300
$16.03+0.57+3.7%$15.42$16.20$15.227,772,000
$15.46+1.34+9.5%$13.96$15.62$13.789,611,600
$14.12-0.18-1.3%$14.09$14.57$13.933,853,900
$14.30-0.42-2.9%$14.74$14.93$14.028,042,600
$14.72-0.02-0.1%$14.74$15.03$13.805,486,200
$14.74+0.16+1.1%$14.81$15.27$14.573,836,900
$14.58-0.08-0.5%$14.66$15.01$14.333,691,700
$14.66+0.45+3.2%$14.37$15.12$14.115,286,400
$14.21+0.08+0.6%$14.10$14.43$13.823,203,300
$14.13-0.12-0.8%$14.53$14.62$13.863,597,300
$14.25-0.27-1.9%$14.62$14.89$14.233,218,200
$14.52+0.575+4.1%$13.82$15.07$13.546,266,600
$13.95-1.605-10.3%$15.55$15.55$13.944,423,900
$15.55+0.51+3.4%$15.17$15.78$15.094,765,400
$15.04+0.27+1.8%$14.96$15.29$14.604,151,200
$14.77-0.57-3.7%$15.41$15.47$14.518,687,400
$15.34-0.02-0.1%$15.83$16.32$14.927,548,600
$15.36-0.89-5.5%$16.31$16.64$15.196,086,100
$16.25+0.09+0.6%$16.14$16.29$15.544,689,700
$16.16+0.28+1.8%$16.06$16.53$15.972,363,500
$15.88-0.15-0.9%$16.05$16.54$15.872,883,800
$16.03+0.33+2.1%$15.37$17.25$15.378,248,100
$15.70-0.58-3.6%$16.06$16.70$15.674,041,900
$16.28+0.09+0.6%$15.88$16.65$15.684,264,700
$16.19-0.07-0.4%$16.04$16.40$15.772,055,100
$16.26-0.11-0.7%$16.38$16.57$16.093,761,800
$16.37-0.39-2.3%$16.97$17.45$15.785,121,100
$16.76-1.12-6.3%$17.58$17.95$16.686,708,100
$17.88-0.15-0.8%$17.87$18.03$17.144,766,100
$18.03-1.46-7.5%$19.25$19.59$18.002,887,300
$19.49+0.34+1.8%$19.30$20.40$19.144,122,500
$19.15+1.39+7.8%$17.57$19.50$17.247,690,600
$17.76+0.16+0.9%$17.80$18.50$17.702,663,100
$17.60-0.03-0.2%$18.41$18.66$16.882,244,400
$17.63+0.55+3.2%$17.28$17.84$17.212,445,400
$17.08-0.99-5.5%$17.59$17.77$16.922,666,400
Ticker
NASDAQ:ERAS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Erasca, Inc. news

Erasca, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 125 in all · newest Nov 20, 2026 · oldest 2021
Decks
12 decks · latest November 2026

Where Erasca, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ERAS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ERASBOATSUnited StatesUSD

Valuation

Price/book 5.2× against a median of 6.6×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.18B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
5.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.51

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Erasca, Inc. · NASDAQ:ERASUS$4.78BUS$4.18Bn/an/an/a5.2×n/a0.1×1.51
Belite Bio, Inc. · NASDAQ:BLTEUS$5.13BUS$5.13Bn/an/an/a6.6×n/a0.0×1.34
SK Biopharmaceuticals Co., Ltd. · KRX:326030US$5.08BUS$4.80B16.9×7.5×20.1×6.7×46.6%0.0×n/a
Veradermics, Incorporated · NYSE:MANEUS$5.04BUS$4.25Bn/an/an/a6.3×n/a0.0×1.13
Liquidia Corporation · NASDAQ:LQDAUS$4.90BUS$4.68Bn/a7.5×n/an/a−15.2%n/a0.84
Dianthus Therapeutics, Inc. · NASDAQ:DNTHUS$4.76BUS$3.92Bn/a1,444×n/a3.8×n/a0.0×0.90
PTC Therapeutics, Inc. · NASDAQ:PTCTUS$4.71BUS$3.12Bn/a2.7×n/an/a−9.2%n/a0.88
Cogent Biosciences, Inc. · NASDAQ:COGTUS$4.65BUS$4.08Bn/an/an/a9.0×n/a0.4×1.30
Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSAUS$4.53BUS$3.97B41.4×4.2×29.9×6.4×11.6%0.0×0.57
Travere Therapeutics, Inc. · NASDAQ:TVTXUS$4.51BUS$4.21Bn/a6.5×n/a200×−18.7%0.0×1.31
Ionis Pharmaceuticals, Inc. · NASDAQ:IONSUS$4.43BUS$4.70Bn/a4.9×n/a11.3×−56.9%5.5×0.40
Median of the othersUS$4.74BUS$4.23B29.2×6.5×25.0×6.6×−12.2%0.0×0.90

Forecasts

6 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
25.10 USD · Analysts' mean
EPS, year to Dec 2026
-1.02 · 9 analysts

Team and board

Officers

OfficerRole
Jonathan E. LimChairman, CEO and Co-founder
David ChackoChief Financial Officer and Chief Business Officer
Charles S. FuchsPresident, Research and Development
Nik ChetwynChief Operating Officer
Ebun GarnerChief Legal Officer
Chandra LovejoyChief Regulatory Affairs Officer
Lisa Tesvich-BonoraChief People Officer
Robert ShoemakerChief Scientific Officer
Shannon MorrisChief Medical Officer

Board

DirectorRole
Jonathan E. LimChairman, CEO and Co-founder
Michael VarneyChair of R&D, SAB Member and Board Director
Alexander W. CasdinBoard Director
James A. BristolBoard Director
Jean I. LiuBoard Director
Julie HambletonBoard Director
Val HardingBoard Director

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−0.8%
Q2 2026Aug 11, 2026 · After close+1.5%
Q1 2026May 11, 2026 · After close−0.6%
Q4 2025Mar 19, 2026+8.2%
Q3 2025Nov 12, 2025 · After close−4.2%
Q2 2025Aug 12, 2025 · After close+3.9%
Q1 2025May 13, 2025 · After close−4.5%
Q4 2024Mar 20, 2025+3.4%
Q3 2024Nov 12, 2024 · After close−4.7%
Q2 2024Aug 12, 2024 · After close+0.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−8.8%
Q4 2023Mar 27, 2024 · After close0.0%
Q3 2023Nov 9, 2023 · After close0.0%
Q2 2023Aug 10, 2023 · After close+11.9%
Q1 2023May 15, 2023 · After close−4.0%
Q4 2022Mar 23, 2023 · After close+1.8%
Q3 2022Nov 9, 2022 · After close+16.6%
Q2 2022Aug 11, 2022 · After close+15.3%
Q1 2022May 12, 2022 · After close−0.2%
Q4 2021Mar 24, 2022 · After close+7.2%

Open Events

Decks

DeckKindSlidesDate
EORTC-NCI-AACR (ENA) Symposium 2026Conference16 slidesNovember 2026
Investor Presentation (August 2026)Investor deck49 slidesAugust 2026
Investor Presentation (January 2026)Investor deck31 slidesJan 12, 2026
Investor Presentation (January 2025)Investor deck51 slidesJan 13, 2025
Investor Presentation (May 2024)Investor deck49 slidesMay 16, 2024
ASCO 2024Conference11 slidesMay 2024
Investor Presentation (January 2024)Investor deck41 slidesJan 9, 2024
Investor Presentation (June 2023)Investor deck35 slidesJun 5, 2023
Investor Presentation (January 2023)Investor deck63 slidesJan 9, 2023
Investor Presentation (December 2022)Investor deck81 slidesDec 9, 2022
All 12 decks
DeckKindSlidesDate
Investor Day (September 2022)Investor day62 slidesSep 7, 2022
Technical Presentation (October 2021)Technical28 slidesOct 25, 2021

Open Decks

Financings

RaiseDate
Public offering of shares
Closed: US$632.5M raised · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead)
Use of proceeds: Fund ERAS-0015 toward three potentially registration-enabling trials and the broader pipeline milestones
Aug 11, 2026
Public offering of common stock
Closed: US$258.8M raised · US$10 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead)
Use of proceeds: Research and development of product candidates and other programs, working capital and general corporate purposes
Jan 23, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Jul 15, 2021.

Price
US$16.00 a share
Shares offered
18,750,000 shares of common stock
Offering size
US$300 million
Underwriters' option
Up to 2,812,500 more shares
Underwriters
J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 7, 2021
Filed publiclyJun 25, 2021
Amended onceJul 12, 2021
Shares registered with an exchangeJul 13, 2021
Declared effective by the SECJul 15, 2021
Final prospectus, with the priceJul 16, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 16, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue3.11M3.81M3.73M2.64M829.0K540.0K310.0K
Gross profit-3.11M-3.81M-3.73M-2.64M-829.0K-540.0K-310.0K
Research and development92.9M115.4M103.8M112.5M73.9M29.6M9.62M
Selling, general and administrative38.6M41.7M37.7M33.0M22.6M7.96M3.68M
Operating income-140.9M-179.6M-141.5M-247.4M-124.9M-109.3M-13.3M
Depreciation and amortization3.11M3.81M3.73M2.64M829.0K540.0K310.0K
EBITDA-137.8M-175.8M-137.8M-244.8M-124.1M-108.7M-13.0M
Interest expense201.4M55.9M336.0K0
Income before tax-124.5M-161.7M-125.0M-242.8M-122.8M-101.7M-12.0M
Income tax00-4.64M27.3M71.4M-1.30M
Net income-124.5M-161.7M-125.0M-242.8M-122.8M-101.7M-12.0M
Earnings per share, basic-0.44-0.69-0.83-1.99-1.85-4.83-0.13
Earnings per share, diluted-0.44-0.69-0.83-1.99-1.85-4.83

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents73.8M67.7M93.1M284.2M360.5M65.4M29.6M
Short-term investments202.3M230.6M219.3M151.4M54.0M53.3M20.8M
Receivables2.50M2.30M100.0K
Current assets286.2M308.8M320.7M444.5M420.0M120.0M51.1M
Property, plant and equipment13.3M16.3M22.3M24.8M16.0M1.85M4.33M
Total assets396.2M502.5M395.3M514.9M501.4M124.8M55.5M
Accounts payable981.0K468.0K2.00M23.0M4.68M878.0K1.38M
Current liabilities28.5M31.4M26.2M48.7M26.2M13.7M2.75M
Total debt47.1M51.9M55.9M55.1M18.8M2.99M3.69M
Total liabilities71.0M79.0M78.6M103.1M44.9M17.4M69.1M
Shareholders' equity325.2M423.5M316.7M411.9M456.5M-114.0M-13.6M
Shares outstanding284.2M283.2M151.1M149.3M119.1M21.9M95.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-95.5M-109.4M-101.2M-103.3M-79.6M-32.7M-10.4M
Capital spending-128.0K-60.0K-1.77M-14.6M-11.2M-947.0K-597.0K
Free cash flow-95.6M-109.5M-103.0M-117.8M-90.8M-33.6M-11.0M
Cash from investing100.4M-156.6M-91.2M-71.1M-64.6M-71.2M-20.9M
Cash from financing1.10M240.7M1.29M98.1M439.4M140.0M16.9M
Share buybacks724.0K800.0K790.0K820.0K1.07M
Change in cash6.07M-25.3M-191.1M-76.3M295.2M36.1M-14.4M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportOct 16, 2026Management or board changeSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
8-K · Current reportAug 24, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
8-K · Current reportAug 10, 2026Management or board changeSEC
144 · Notice of proposed saleJul 21, 2026Other filingsSEC
8-K · Current reportJul 14, 2026Current reportSEC
424B5 · ProspectusJul 14, 2026Offer documentSEC
424B5 · ProspectusJul 13, 2026Offer documentSEC
8-K · Current reportJul 13, 2026Current reportSEC
S-3ASR · Registration statementJul 13, 2026Offer documentSEC
8-K · Current reportJun 30, 2026Meeting outcomeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportApr 27, 2026Current reportSEC
8-K · Current reportApr 27, 2026Current reportSEC
8-K · Current reportApr 21, 2026Current reportSEC
144/A · Notice of proposed sale, amendedApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
8-K · Current reportJan 29, 2026Current reportSEC
8-K · Current reportJan 22, 2026Current reportSEC
424B5 · ProspectusJan 22, 2026Offer documentSEC
8-K · Current reportJan 20, 2026ResultsSEC
424B5 · ProspectusJan 20, 2026Offer documentSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJan 14, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
144 · Notice of proposed saleSep 15, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 25, 2025Other filingsSEC
CORRESP · Letter to the SECAug 20, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
S-3 · Registration statementAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
144 · Notice of proposed saleJul 15, 2025Other filingsSEC
8-K · Current reportJun 26, 2025Meeting outcomeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
144 · Notice of proposed saleJun 16, 2025Other filingsSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
144 · Notice of proposed saleMay 15, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
144 · Notice of proposed saleApr 15, 2025Other filingsSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 29, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
8-K · Current reportOct 24, 2024Current reportSEC
144 · Notice of proposed saleOct 15, 2024Other filingsSEC
144 · Notice of proposed saleSep 16, 2024Other filingsSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
144 · Notice of proposed saleJul 15, 2024Other filingsSEC
8-K · Current reportJun 24, 2024Meeting outcomeSEC
8-K · Current reportJun 24, 2024Current reportSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
144 · Notice of proposed saleJun 17, 2024Other filingsSEC
SC 13G · Big-stake noticeMay 31, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 29, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 28, 2024Big-stake noticeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
424B5 · ProspectusMay 17, 2024Offer documentSEC
8-K · Current reportMay 17, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 17, 2024Other filingsSEC
8-K · Current reportMay 16, 2024Material contractSEC
144 · Notice of proposed saleMay 15, 2024Other filingsSEC
CORRESP · Letter to the SECMay 14, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2024Other filingsSEC
S-3 · Registration statementMay 9, 2024Offer documentSEC
S-8 · Registration statement for employee plansMay 9, 2024Offer documentSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
144 · Notice of proposed saleApr 15, 2024Other filingsSEC
8-K · Current reportMar 28, 2024Material contractSEC
10-K · Annual reportMar 27, 2024Annual reportSEC
8-K · Current reportMar 27, 2024ResultsSEC
144 · Notice of proposed saleMar 15, 2024Other filingsSEC
144 · Notice of proposed saleFeb 15, 2024Other filingsSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 30, 2024Big-stake noticeSEC
144 · Notice of proposed saleJan 16, 2024Other filingsSEC
8-K · Current reportJan 9, 2024Current reportSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC

This page holds 200 of 358 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Erasca, Inc.’s releases · as of Nov 5, 2026

Common shares
350,956,416
Fully diluted
350,956,416

Fully diluted

LineSharesAs of
Common shares350,956,416Nov 5, 2026

Share count over time

CountShares
Nov 5, 2026350,956,416

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Frazier Life Sciences Management, L.P.29.5M8.4%US$432MSep 30, 2026
T. Rowe Price25.8M7.4%US$379MSep 30, 2026
Vanguard24.8M7.1%US$364MSep 30, 2026
BlackRock23.7M6.8%US$348MSep 30, 2026
Rtw Investments, LP22.4M6.4%US$329MSep 30, 2026
Venrock Adviser, LLC20.1M5.7%US$295MSep 30, 2026
State Street13.8M3.9%US$203MSep 30, 2026
Siren, L.L.C.13.2M3.8%US$193MSep 30, 2026
Capital Group9.36M2.7%US$137MSep 30, 2026
Paradigm Biocapital Advisors LP8M2.3%US$117MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
ARCH Venture Management, LLC7.09M2.0%US$104MSep 30, 2026
Geode Capital6.72M1.9%US$98.6MSep 30, 2026
Logos Global Management LP5.9M1.7%US$86.5MSep 30, 2026
Affinity Asset Advisors, LLC5.59M1.6%US$82MSep 30, 2026
Soleus Capital Management, L.P.5.11M1.5%US$74.9MSep 30, 2026
Cormorant Asset Management, LP5M1.4%US$73.3MSep 30, 2026
Goldman Sachs4.35M1.2%US$63.7MSep 30, 2026
AllianceBernstein4.15M1.2%US$60.9MSep 30, 2026
Assenagon Asset Management S.A.4.13M1.2%US$60.5MSep 30, 2026
Vivo Capital, LLC4.02M1.1%US$58.9MSep 30, 2026
Bank of America3.83M1.1%US$56.2MSep 30, 2026
Woodline Partners LP3.23M0.92%US$47.4MSep 30, 2026
UBS3.02M0.86%US$44.3MSep 30, 2026
Janus Henderson3.01M0.86%US$44.1MSep 30, 2026
EcoR1 Capital, LLC2.95M0.84%US$43.2MSep 30, 2026
Jennison Associates LLC2.69M0.77%US$39.4MSep 30, 2026
Samlyn Capital, LLC2.54M0.72%US$37.3MSep 30, 2026
Schwab2.46M0.70%US$36.1MSep 30, 2026
Fidelity2.46M0.70%US$36MSep 30, 2026
Stempoint Capital LP2.26M0.64%US$33.1MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.25M0.64%US$33MSep 30, 2026
Northern Trust2.21M0.63%US$32.3MSep 30, 2026
BNP Paribas2.08M0.59%US$30.5MSep 30, 2026
Nuveen2M0.57%US$29.4MSep 30, 2026
Caption Management, LLC1.88M0.54%US$27.6MSep 30, 2026
Victory Capital1.84M0.53%US$27MSep 30, 2026
Dimensional1.76M0.50%US$25.8MSep 30, 2026
Polar Capital Holdings Plc1.67M0.48%US$24.5MSep 30, 2026
Renaissance Technologies1.61M0.46%US$23.6MSep 30, 2026
Federated Hermes, Inc.1.57M0.45%US$23MSep 30, 2026
a16z Capital Management, L.L.C.1.43M0.41%US$21MSep 30, 2026
Rock Springs Capital Management LP1.41M0.40%US$20.6MSep 30, 2026
Evergreen Quality Fund GP, Ltd.1.38M0.39%US$20.2MSep 30, 2026
Fred Alger Management, LLC1.37M0.39%US$20.1MSep 30, 2026
Silverarc Capital Management, LLC1.33M0.38%US$19.5MSep 30, 2026
Qube Research & Technologies Ltd1.25M0.36%US$18.4MSep 30, 2026
Integral Health Asset Management, LLC1.13M0.32%US$16.6MSep 30, 2026
JPMorgan1.12M0.32%US$16.1MSep 30, 2026
D. E. Shaw & Co., Inc.972K0.28%US$14.2MSep 30, 2026
First Turn Management, LLC913K0.26%US$13.4MSep 30, 2026

This page holds 50 of 261 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund8.38M2.4%US$154MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF7.45M2.1%US$136MJun 30, 2026
T. Rowe Price Capital Appreciation Fund6.95M2.0%US$127MJun 30, 2026
iShares Russell 2000 ETF5.14M1.5%US$94.1MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.3.33M0.95%US$61.1MJun 30, 2026
Vanguard Extended Market Index Fund2.75M0.78%US$50.3MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.2.58M0.74%US$47.3MJun 30, 2026
Select Biotechnology Portfolio2.53M0.72%US$32.5MMay 31, 2026
Fidelity Small Cap Index Fund2.41M0.69%US$43.7MJul 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund1.79M0.51%US$32.7MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Russell 2000 Growth ETF1.67M0.48%US$30.5MJun 30, 2026
JNL/T. Rowe Price Capital Appreciation Fund1.52M0.43%US$27.9MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.44M0.41%US$26.3MJun 30, 2026
Victory Pioneer Select Mid Cap Growth Fund1.33M0.38%US$17.1MMay 31, 2026
iShares Biotechnology ETF1.33M0.38%US$24.3MJun 30, 2026
Fidelity Extended Market Index Fund1.23M0.35%US$15.8MMay 31, 2026
Schwab U.S. Small-Cap ETF1.15M0.33%US$14.7MMay 31, 2026
AB Small Cap Growth Portfolio1000K0.28%US$18.3MJun 30, 2026
Vanguard Russell 2000 Index Fund974K0.28%US$12.5MMay 31, 2026
Alger Small Cap Focus Fund954K0.27%US$17.3MJul 31, 2026
PGIM Jennison Health Sciences Fund878K0.25%US$11.3MMay 29, 2026
AB Discovery Growth Fund, Inc.852K0.24%US$15.6MJun 30, 2026
Nuveen Quant Small Cap Equity Fund734K0.21%US$13.3MJul 31, 2026
BlackRock Health Sciences Opportunities Portfolio710K0.20%US$9.11MMay 29, 2026
Vy(R) T. Rowe Price Capital Appreciation Portfolio691K0.20%US$12.7MJun 30, 2026
Vanguard Explorer Fund685K0.20%US$12.4MJul 31, 2026
T. Rowe Price Capital Appreciation Equity ETF563K0.16%US$10.3MJun 30, 2026
Federated Hermes Kaufmann Fund556K0.16%US$10.1MJul 31, 2026
T. Rowe Price Small-Cap Value Fund, Inc.551K0.16%US$10.1MJun 30, 2026
Schwab Small-Cap Index Fund536K0.15%US$9.73MJul 31, 2026
Vanguard Health Care Index Fund510K0.15%US$6.55MMay 31, 2026
Penn Series Flexibly Managed Fund496K0.14%US$9.08MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.488K0.14%US$8.95MJun 30, 2026
Fidelity Total Market Index Fund447K0.13%US$5.75MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF403K0.11%US$7.31MJul 31, 2026
EQ/AB Small Cap Growth Portfolio398K0.11%US$7.29MJun 30, 2026
Invesco Dorsey Wright Healthcare Momentum ETF381K0.11%US$6.92MJul 31, 2026
Fidelity Series Total Market Index Fund365K0.10%US$4.69MMay 31, 2026
Master Small Cap Index Series362K0.10%US$6.63MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund346K0.10%US$6.29MJul 31, 2026
U.S. Small Cap Portfolio336K0.10%US$6.1MJul 31, 2026
SmallCap Growth Fund I328K0.09%US$5.95MJul 31, 2026
Federated Hermes Kaufmann Small Cap Fund326K0.09%US$5.91MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF319K0.09%US$5.85MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF295K0.08%US$5.4MJun 30, 2026
Nuveen Quant Small/Mid Cap Equity Fund293K0.08%US$5.32MJul 31, 2026
Nuveen Small Cap Blend Index Fund288K0.08%US$5.22MJul 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF283K0.08%US$3.63MMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account282K0.08%US$5.17MJun 30, 2026
Dimensional U.S. Small Cap ETF263K0.08%US$4.78MJul 31, 2026

This page holds 50 of 244 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Garner Ebun
Officer: Chief Legal Officer
Sale80,000USD 16.40US$1.31MApr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Jonathan E. Lim10.40%37MJun 30, 2026Schedule 13G
Rtw Investments, LP6.40%22.4MSep 30, 2026Schedule 13G
Venrock Healthcare Capital Partners III, L.P.5.30%16.4MMar 31, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.5.30%15MJun 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Lin Wei
Other companies: TCGX Acquisition Corp. (Director · Since at least Aug 4, 2026); Revolution Medicines, Inc. (Chief Medical Officer · Since at least Mar 21, 2024); 2Seventy Bio Inc (Director · Mar 7, 2023 – May 13, 2025 · Past)
Chief Medical Officer · Jul 15, 2021 – Feb 1, 2023 · Past
James Bristol
Other companies: Ernexa Therapeutics Inc. (Chairman · Since at least Oct 30, 2023); Deciphera Pharmaceuticals LLC (Director · Jun 11, 2024 – Jun 11, 2024 · Past)
Director · Since at least Jan 1, 2024
Jean Liu
Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); Seagen Inc (Chief Legal Officer · Dec 14, 2023 – Dec 14, 2023 · Past)
Director · Since at least Jan 1, 2024
Alexander W. Casdin
Other companies: Sientra Inc (Director · Jun 15, 2023 – Jun 15, 2023 · Past)
Director · Since at least Jul 15, 2021
Charles S. Fuchs
Other companies: CytomX Therapeutics, Inc. (Director · Since at least Oct 23, 2017)
President, Research and Development · Since at least Aug 10, 2026
Ebun Garner
Other companies: Alphatec Holdings, Inc. (General Counsel and SVP · May 15, 2012 – Dec 12, 2016 · Past)
Chief Legal Officer · Since at least Jul 15, 2021
Chandra LovejoyChief Regulatory Affairs Officer · Since at least Nov 5, 2026
David ChackoChief Financial Officer and Chief Business Officer · Since at least Nov 5, 2026
Jonathan E. LimChairman, CEO and Co-founder · Since at least Sep 10, 2026
Julie HambletonBoard Director · Since at least Nov 5, 2026
All 17 people
PersonSeat
Lisa Tesvich-BonoraChief People Officer · Since at least Nov 5, 2026
Michael VarneyChair of R&D, SAB Member and Board Director · Since at least Nov 5, 2026
Nik ChetwynChief Operating Officer · Since at least Nov 4, 2026
Robert ShoemakerChief Scientific Officer · Since at least Nov 12, 2025
Shannon MorrisChief Medical Officer · Since at least Feb 5, 2024
Valerie Denise Harding StartDirector · Since at least Jun 24, 2025
Val HardingBoard Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Erasca, Inc.